Amylin, Lilly seek expanded use of Byetta in US
This article was originally published in Scrip
Executive Summary
Biotech Amylin Pharmaceuticals and its pharma partner Eli Lilly are seeking US approval for an expanded use of their injectable Type II diabetes drug Byetta (exenatide) as an add-on therapy for patients taking insulin.